CYTK - Cytokinetics, Incorporated
7.49 +0.28 (3.88%)
After hours: 5:37PM EST
| Previous Close | 7.34 |
| Open | 7.35 |
| Bid | 7.50 x 2200 |
| Ask | 7.94 x 1300 |
| Day's Range | 7.17 - 7.45 |
| 52 Week Range | 5.90 - 10.00 |
| Volume | 1,139,902 |
| Avg. Volume | 312,541 |
| Market Cap | 394.466M |
| Beta (3Y Monthly) | 2.08 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.22 |
| Earnings Date | Feb 21, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.33 |
- Zacks•2 hours ago
Cytokinetics (CYTK) Reports Q4 Loss, Tops Revenue Estimates
Cytokinetics (CYTK) delivered earnings and revenue surprises of 12.73% and 171.40%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•3 hours ago
Cytokinetics: 4Q Earnings Snapshot
The South San Francisco, California-based company said it had a loss of 48 cents per share. The biopharmaceutical company posted revenue of $9.4 million in the period. For the year, the company reported ...
- GlobeNewswire•3 hours ago
Cytokinetics Reports Fourth Quarter 2018 Financial Results
Company Provides 2019 Financial Guidance and Expected Milestones Reduced Operating Expenses vs. 2018; Over Two Years of Cash Based on Current Burn Rate Interim Analysis for.
- GlobeNewswire•10 hours ago
Amgen, Cytokinetics and Servier Announce Start of METEORIC-HF, the Second Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. and SURESNES, France, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Amgen (AMGN), Cytokinetics, Incorporated (CYTK) and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure), the second Phase 3 clinical trial of omecamtiv mecarbil, a novel cardiac myosin activator, is open to enrollment. Omecamtiv mecarbil is being developed for the potential treatment of heart failure with reduced ejection fraction (HFrEF). METEORIC-HF is designed to evaluate the effect of treatment with omecamtiv mecarbil compared to placebo on exercise capacity as determined by cardiopulmonary exercise testing (CPET) in patients with HFrEF.
- PR Newswire•10 hours ago
Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
THOUSAND OAKS, Calif., SOUTH SAN FRANCISCO, Calif., and SURESNES, France, Feb. 21, 2019 /PRNewswire/ -- Amgen (AMGN), Cytokinetics, Incorporated (CYTK) and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure), the second Phase 3 clinical trial of omecamtiv mecarbil, a novel cardiac myosin activator, is open to enrollment. Omecamtiv mecarbil is being developed for the potential treatment of heart failure with reduced ejection fraction (HFrEF). METEORIC-HF is designed to evaluate the effect of treatment with omecamtiv mecarbil compared to placebo on exercise capacity as determined by cardiopulmonary exercise testing (CPET) in patients with HFrEF.
- GlobeNewswire•yesterday
Cytokinetics Announces Initiation of Phase 1 Clinical Study of AMG 594, a Cardiac Troponin Activator
Cytokinetics, Incorporated (CYTK) today announced that the first subject has been dosed in a Phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 594 in healthy subjects. AMG 594 is a cardiac troponin activator, discovered under a joint research program conducted between Amgen and Cytokinetics. The study is being conducted by Amgen in collaboration with Cytokinetics.
- Zacks•7 days ago
The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna
The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna
- Zacks•7 days ago
Will Cytokinetics (CYTK) Report Negative Earnings Next Week? What You Should Know
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks•8 days ago
5 Tiny Biotech Stocks With Superb Growth Potential
A spurt in deal-making has boosted the sector this year which retains the ability to provide outsized gains.
- GlobeNewswire•14 days ago
Cytokinetics to Announce Fourth Quarter Results on February 21, 2019
Cytokinetics, Incorporated (CYTK) today announced that it is scheduled to report fourth quarter results on February 21, 2019 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future. The conference call will be simultaneously webcast and can be accessed from the homepage and in the Investors & Media section of Cytokinetics’ website at www.cytokinetics.com.
- GlobeNewswire•last month
Cytokinetics Announces Receipt of FDA Feedback Regarding Reldesemtiv in Patients With SMA
Cytokinetics, Incorporated (CYTK) today announced that it has received feedback from the U.S. Food and Drug Administration (FDA) that the Six Minute Walk Test (6MWT) is an acceptable primary efficacy endpoint for a potential registration program for reldesemtiv in patients with spinal muscular atrophy (SMA) who have maintained ambulatory function. In collaboration with Astellas, Cytokinetics is developing reldesemtiv as a potential treatment for people with SMA and certain other debilitating diseases and conditions associated with skeletal muscle weakness and/or fatigue. The companies are discussing potential next steps regarding the ongoing development program for reldesemtiv in this patient population.
- Simply Wall St.•2 months ago
Could Cytokinetics, Incorporated’s (NASDAQ:CYTK) Investor Composition Influence The Stock Price?
The big shareholder groups in Cytokinetics, Incorporated (NASDAQ:CYTK) have power over the company. Institutions often own shares in more established companies, while it's not unusual to see insiders own a Read More...
- Insider Monkey•2 months ago
Hedge Funds Are Dumping Cytokinetics, Inc. (CYTK)
It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren’t usually symmetrically distributed and index […]
- GlobeNewswire•2 months ago
Cytokinetics Announces New Data Presented at the International Symposium on ALS/MND
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2018 -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new data were presented at the 29th International Symposium on.
- GlobeNewswire•3 months ago
Cytokinetics Announces Initiation of Phase 1 Clinical Trial of CK-3773274, a Cardiac Myosin Inhibitor
Cytokinetics, Incorporated (CYTK) today announced the first subject has been dosed in a Phase 1 double-blind, randomized, placebo-controlled, multi-part, single and multiple ascending dose clinical trial of CK-3773274 (CK-274) in healthy adult subjects. CK-274 is a novel cardiac myosin inhibitor, discovered by company scientists, in development for the potential treatment of hypertrophic cardiomyopathy (HCM). “The start of clinical trials for CK-274 marks an important milestone in our continuing innovation of potential sarcomere-directed medicines,” said Fady I. Malik, M.D., Ph.D., Cytokinetics’ Executive Vice President of Research & Development.
- Benzinga•3 months ago
Jim Cramer Gives His Opinion On Netflix, Kraft Heinz And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said he isn't a fan of Netflix, Inc. (NASDAQ: NFLX ) because the content isn't as compelling as it once was. He sees it as a good story, but ...
- GlobeNewswire•3 months ago
Analysis: Positioning to Benefit within Abeona Therapeutics, Great Lakes Dredge & Dock, Imprimis Pharmaceuticals, Alliant Energy, Cytokinetics, and Aurinia Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•3 months ago
Cytokinetics Completes Enrollment in FORTITUDE-ALS, Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS
Cytokinetics, Incorporated (CYTK) today announced the completion of patient enrollment in FORTITUDE-ALS (Functional Outcomes in a Randomized Trial of Investigational Treatment with CK-2127107 to Understand Decline in Endpoints – in ALS), the Phase 2 clinical trial designed to assess the change from baseline in the percent predicted slow vital capacity (SVC) and other measures of skeletal muscle function after 12 weeks of treatment with reldesemtiv (formerly CK-2127107). In collaboration with Astellas Pharma Inc. (TSE:4503) (“Astellas”), Cytokinetics is developing reldesemtiv, a next-generation fast skeletal muscle troponin activator (FSTA), as a potential treatment for people living with debilitating diseases and conditions associated with skeletal muscle weakness and/or fatigue.
- GlobeNewswire•3 months ago
Cytokinetics Announces Five Presentations at the International Symposium on ALS/MND
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2018 -- Cytokinetics, Inc. (Nasdaq: CYTK) today announced five poster presentations at the 29th International Symposium on ALS/MND in.
- Zacks•3 months ago
Cytokinetics Sees Hammer Chart Pattern: Time to Buy?
Cytokinetics has been struggling lately, but the selling pressure may be coming to an end soon.
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of CYTK earnings conference call or presentation 1-Nov-18 8:30pm GMT
Q3 2018 Cytokinetics Inc Earnings Call
- Zacks•4 months ago
Cytokinetics (CYTK) Reports Q3 Loss, Tops Revenue Estimates
Cytokinetics (CYTK) delivered earnings and revenue surprises of 24.53% and 377.18%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•4 months ago
Cytokinetics: 3Q Earnings Snapshot
On a per-share basis, the South San Francisco, California-based company said it had a loss of 40 cents. The biopharmaceutical company posted revenue of $10.6 million in the period. Cytokinetics shares ...
